康宁杰瑞
ALPHAMAB ONCOLOGY

Alphamab Oncology Investor Presentation

May, 2021

Disclaimer

This presentation has been prepared by Alphamab Oncology (the “Company”) solely for use at the presentation held in 2021.

The information contained in this presentation has not been independently verified. No representation or warranty, expressed or implied, is made and no reliance should be placed on the accuracy, fairness or completeness of the information contained herein. The information and opinions contained in this presentation are provided as of the date of this presentation or the respective cut-off date in respect of the clinical trial data, are subject to change without notice and will not be updated or otherwise revised to reflect any developments, which may occur after the date of the presentation. Neither the Company nor any of its affiliates, advisers or representatives accepts any liability whatsoever for any actual or consequential loss or damages howsoever arising from the provision or use of any information contained in this presentation. The Company may alter, modify or otherwise change in any manner the contents of this presentation, without obligation to notify any person of such alternations, modifications or changes.

This presentation contains statements that constitute forward-looking statements. These statements can be recognized by the use of words such as “expects,” “plan,” “will,” “estimates,” “projects,” “intends,” or words of similar meaning or intent. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors and assumptions. The Company has no obligation and does not undertake to revise forward-looking statements contained in this presentation to reflect future events or circumstances. Accordingly, you should not place undue reliance on any forward-looking information.

This presentation is highly confidential, is being presented solely for your information and for your use and may not be copied, reproduced or redistributed to any other person in any manner without the Company’s prior written consent. Unauthorized copying, reproduction or redistribution of this presentation could be limited or prohibited by the securities laws of various jurisdictions.

This presentation is for information purposes only and does not constitute or form part of, and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company, any of its holding companies, or any of its subsidiaries in any jurisdiction or an inducement to enter into investment activity. No part of this presentation, nor the fact of its distribution, shall form the basis of or be relied upon in connection with any contract, commitment or investment decision whatsoever. Any decision to purchase or subscribe for any securities of the Company should be made after seeking appropriate professional advice. By attending or receiving this presentation you acknowledge that you will be solely responsible for your own assessment of the business, the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.

No securities of the Company may be offered, sold or transferred within the United States or to, or for the account or benefit of U.S. persons, without registration with the United States Securities and Exchange Commission, except as pursuant to an exemption from, or in a transaction not subject to, such registration requirements. The Company has not registered and does not intend to register any securities of the Company under the U.S. Securities Act of 1933, as amended. There will be no public offering of any securities by the Company in the United States. In Hong Kong, no securities of the Company may be offered to the public unless a prospectus in connection with the Offering for subscription of such shares has been formally approved by The Stock Exchange of Hong Kong Limited in accordance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) and duly registered by the Registrar of Companies in Hong Kong. The securities referred to herein have not been and will not be registered under the applicable securities laws of the People’s Republic of China (the “PRC”), and may not be offered or sold within the PRC or to any national, resident or citizen of the PRC.

By attending this presentation, participants agree not to remove this presentation, or any materials provided in connection herewith, from the conference room or online platform where such presentation or materials are provided. Participants further agree not to photograph, copy or otherwise reproduce these materials during the presentation or while in the conference room. Participants must return this presentation and all other materials provided in connection herewith to the Company at the completion of the presentation. By attending this presentation, you are agreeing to be bound by the restrictions and other limitations set forth herein. Any failure to comply with these limitations may constitute a violation of law and may lead to legal or regulatory action.

Agenda

1. 2020 Overview
2. R&D Progress
3. Clinical Progress
4. Operation Progress
5. 2021 Catalyst
6. Financial Overview
7. Q&A

康宁杰瑞
ALPHAMAB ONCOLOGY



01

2020 Overview

康宁杰瑞 ALPHAMAB ONCOLOGY

We are a leading clinical-stage biopharmaceutical company in China with a fully-integrated proprietary biologics platform in bispecifics and protein engineering, delivering world-class innovative therapeutic biologics to cancer patients globally.

Track Record

- Founded by a visionary scientist who has made contributions to over 100 patents and patent applications since 2011
- Strong in-house R&D contributed to the CMC processes of many biosimilar candidates including 4 out of 11 biosimilar BLAs filed in China from 2017 to 2019

Global Rights

- All in-house developed candidates
- Global rights (IP, Commercial)
- ＞30 ongoing global or China clinical trials

Innovation

- All in-house developed proprietary platforms including sdAb/mAb, CRIB, CRAM, BADC, BIMC, TIMC, GIMC and CIMC
- Robust first-in-class global next-generation product pipeline: 16 products, with 1 BLA submitted, 3 in late clinical stage, and 3 IND enabling

Integrated Platform

- Fully-integrated platform consisting of drug discovery, development, manufacturing and near-term commercialization

Pipeline overview

Stage	Drug candidates	Target(s)	Platform	Rights	Key Indications	Pre-clinical	Dose escala-tion	Proof of concept	Pivotal	NDA
Late-stage	**KN046**	PD-L1/CTLA-4 bispecific	sdAb/ mAb	Global	NSCLC, Thymic, HCC, Pancreatic, ESCC, TNBC					
	KN026	HER2/HER2 bispecific	CRIB	Global	HER2-positive BC, GC/GEJ					
	KN026 +KN046	Target therapy +IO combo	Biomarker driven	Global	HER2-positive solid tumors					
	KN035	subQ PD-L1	sdAb/ mAb	Global Co-development	MSI-H, BTC, Sarcoma, TMB-H, MSS endometrial					NDA submitted in 2020Q4
Clinical/ IND	**KN019**	B7	Fusion protein	Global	RA, lupus, renal transplant, GvHD			Phase II ongoing		
	KN052	PD-L1/OX40 bispecific	CRIB	Global	Solid tumors					
	KN062	None RBD conformation bispecific	CRIB	Global	COVID-19					
	JSKN-003	HER2 ADC	BADC	Global	HER2-positive/low solid tumors					
Pre-clinical	**JSKN-001**	Undisclosed	CRIB	Global	Solid tumors					
	JSKN-002	Undisclosed	GIMC	Global	Solid tumors					
	JSKN-004	Undisclosed	TIMC	Global	Solid tumors					
	JSKN-005	Undisclosed	CIMC	Global	Solid tumors					
	JSKN-006	Undisclosed	BIMC	Global	Solid tumors					
	KN053	Undisclosed bispecific	sdAb/ mAb	Global	Solid tumors					
	KN055	Undisclosed bispecific	sdAb/mAb, fusion protein	Global	Solid tumors					
	KN058	Undisclosed bispecific	sdAb/mAb, fusion protein	Global	Solid tumors					
	KN138	None-blocking CTLA-4	sdAb/ mAb	Global	Solid tumors					

Major progresses

Program Progress

- ✓ **1 BLA under Priority Review by NMPA**: Envafolimab(KN035) MSI-H/dMMR advanced solid tumors
- ✓ **4 pivotal trials kicked off**:
  - KN046 NSCLC
  - KN046 thymic carcinoma
  - KN046+KN026 HER2+ solid tumors
  - KN035 soft tissue sarcoma in US by Tracon
- ✓ **3 Orphan Drug Designation granted by US FDA** :
  - KN035 BTC
  - KN046 thymic epithelial tumor
  - KN026+KN046 gastric cancer
- ✓ **9 IND approved**:
  - 6 in China: KN046 late stage GI (combo Donafenib), KN046 solid tumors and blood tumors including HCC (combo Ningetinib), KN046+KN026 HER2-positive or low solid tumors, KN026 HER2-positive or low mBC (mono or combo docetaxel), KN026 HER2-positive mBC (combo palbociclib or palbociclib+fulvestrant)
  - 3 in US: KN046 thymic carcinoma, KN046 PD-(L)1 refractory NSCLC, KN035 soft tissue sarcoma
- ✓ **8 clinical data presentations** at ASCO, AACR, SITC and WCLC

Major progresses

Operation Progress

- ✓ **10 partnerships** :
  - KN026 : **Sanofi, Pfizer**
  - KN046 : **Pfizer**, Zelgen (泽璟)，Sunny Lake (东阳光)，Kintor (开拓)，Sinovent (信诺维)，InxMed (应世)
  - KN035 : Simcere (先声)，Tracon
  - KN062 : Institut Pasteur Shanghai (中科院上海巴斯德)
- ✓ **Drug production license** : The 2x2,000L production lines of the new manufacturing facilities obtained Drug Production License
- ✓ **Further expansion of management team** :
  - CFO, Mr. Weihao Xu
  - CMO, Dr. Johannes Nippgen, Ph.D.
- ✓ **Establishing operation center in Shanghai**

Finance and capital market

- ✓ **Increased R&D expenses** : increased from RMB166.7 million for FY2019 to RMB331.2 million for FY2020, primarily due to expansion and advancement of clinical trials
- ✓ **Healthy cash reserve** : cash balance of RMB2,021 million as of December 31, 2020
- ✓ **Inclusion to the Hang Seng Composite Index**, **Hang Seng Healthcare Index**, **Southbound Stock Connect**

康宁杰瑞
ALPHAMAB ONCOLOGY



02

R&D Progress

Cutting-edge R&D Platforms Continuously Advance R&D Pipeline

sdAb

- Smaller and more stable with a compact structure
- Ideal building blocks for multifunctional biologics
- Proof-of-concept: KN035[1], KN046[2], KN052



CRIB

- Maintain full-length antibody properties
- Optimized for commercial-scale manufacturing
- Proof-of-concept: KN026[3]



CRAM

- A single streamlined process to produce multiple mAbs with adjustable pre-determined ratio



Note:
1. First BLA submitted in 2020
2. Pivotal trial stage
3. Pivotal trial stage

Expanded Multi-Functional Platforms Transform Next Generation R&D Portfolio



KN052: Anti-PD-L1/OX40 Bispecific Antibody



Humanized VHH to PD-L1, Antagonist

Human Fab to OX40, Agonist

Wildtype IgG1Fc

- PD-L1 antagonist and OX40 agonist activity in one molecule
- Tandem structure for antigen binding domain arrangement to attenuate anti-OX40 toxicity
- Wildtype IgG1 Fc with full Fc function

KN052 shows synergistic antitumor activity in MC38 tumor model



JSKN003: Anti-HER2 Paratopes Bispecific ADC



- Targeting two different paratopes of HER2 (KN026)
- Site specific conjugation, DAR 3-4
- Better serum stability for better safety potential
- Strong activity in HER2 high and low expression cells in CDX Model

JSKN003 shows strong anti-tumor activity in CDX model

BxPC-3 CDX Model (HER2 low)



N87 CDX Model (HER2 high)



KN062: Bispecific COVID-19 Neutralization Antibody



- Combination of two antibodies targeting different paratopes outside of escaping mutant
- Potential to combo with approved COVID-19 antibodies

3c1+2H2 combination show stronger neutralization activity than mono paratope treatment



康宁杰瑞
ALPHAMAB ONCOLOGY



03

Clinical Progress

Clinical Updates

KN046	KN026	KN035	KN019
Dual blockade of PD-L1 and CTLA-4	Dual blockade of HER2 domain II and IV	Subcutaneous PD-L1	A safe option for autoimmune diseases

Enable earlier lines of therapies for improved efficacy and safety

Potential for all settings of HER2 aberration
Synergy with KN046 through immune modulation

Subcutaneous PD-L1 for maintenance therapy

Supplement to immunotherapies for AE management







KN046: PD-L1/CTLA-4 BsAb

Mechanism of Action



Highlights

1) Targeted drug delivery

- Engineered to enable the anti-PD-L1 sdAb to dominate drug distribution
- Targeted drug delivery to enrich KN046 in tumor-related micro-environment and limit exposure to non-tumor tissues

2) Different CTLA-4 binding epitope

- Our anti-CTLA-4 sdAb mainly binds outside the interface and blocks the CTLA-4/B7 with steric hindrance
- Lead to a potentially improved safety profile

3) Preservation of Fc-mediated effector functions

- Preserves the full Fc functions for Treg Depletion

4) Strong Scientific base to support targeting CTLA-4 and PD-L1 with Bispecifics

KN046 Major Clinical Trials

Stage	Indication	Mono/Combo	Pre-clinical	Dose escala-tion	Proof of concept	Pivotal	NDA	Expected timeline
4 Pivotal trials	**1L NSCLC, sq**	+chemo					★	BLA 2022H1
	Thymic carcinoma	Mono					★	BLA 2022H1
	PD-(L)1 refractory NSCLC	+Lenvatinib					★	BLA 2023H2
	1L Pancreatic Cancer	+chemo					★	FPI 2021H2
Key phase 2 trials ongoing	**1L Pancreatic Cancer**	+chemo						Ongoing
	Driver mutation positive NSCLC	+chemo						Ongoing
	Stage III NSCLC	+RT						Ongoing
	1L TNBC	+nab-paclitaxel						Ongoing
	1L ESCC	+chemo						Ongoing

★ Pivotal Trial

Note: FPI – first patient in

KN046-CHN-001 and KN046-201 in ICI Refractory Patients

1 Preliminary efficacy of KN046 monotherapy in anti-PD1 refractory NSCLC

Waterfall plot (DCR 50%)



Progression-free survival (2.8 months)



Overall survival (mOS not reached yet)



2 Comparable trials in NSCLC

	KN046-CHN-001 & KN046-201*	Fujita 2019	Yuki Katayama 2019	ENCOR-601
Drug	KN046 monotherapy	Atezolizumab	Anti-PD-1 I-O	Entinostat+ Pembrolizumab
Patients #	24	18	35	72
ORR	8.3% (DCR 50%)	0 (DCR 38.9%)	5.9% (DCR 42.9%)	10% (DCR 60%)
mPFS	2.8 months	1.7 months	2.7 months	2.8 months
mOS	Not reached 12-month OS: 54%	Not reported	7.4 months	Not reported

Notes:

1. Data not mature yet

KN046-201 2L NSCLC (2021 WCLC)

1 PFS and OS benefits for squamous and non-squamous NSCLC patients

PFS



OS



mPFS 3.68 months (95%CI 3.35, 7.29):

- non-sq NSCLC **3.58 months** (2.46, 5.52)
- sq NSCLC **7.29 months** (3.68, 9.23)

mOS not reached yet:

- 6-month OS rate **85.6%**
- 12-month OS rate **69.7%**

2 Numerically higher mPFS and mOS than PD-1s

	KN046-201	Keynote001	CheckMate057	CheckMate017
Indication	NSCLC 2L	NSCLC 2L	NSCLC (non-sq) 2L	NSCLC (sq) 2L
Drug	KN046	Pembrolizumab	Nivolumab	Nivolumab
Patients #	64	394	292	135
mPFS	7.3 (sq), 3.6 (non-sq)	3	2.3	3.5
mOS	13.6* (sq), Not reached (non-sq)	9.3	12.2	9.2

Notes: Data not mature yet

KN046-AUS-01 Rare Thoracic Tumors (2021 WCLC)



- **ODD (Orphan Drug Designation) awarded by US FDA**
- **Phase II pivotal trial in China and US ongoing**

Response observed in 3 patients with thymic epithelial out of 4 in total :

- ORR: **75% (3/4)**
- DCR: **100% (4/4)**

KN046-IST-01 ESCC (with concurrent chemoradiation therapy) (2021 ASCO GI)

1 Waterfall plot before & after KN046 treatment



	1mg/kg (N=3)	3mg/kg (N=11)	5mg/kg (N=4)	All (N=18)
ORR	1 (33.3%)	**6 (54.5%)**	1 (25.0%)	8 (44.4%)
DCR	2 (66.7%)	**11 (100.0%)**	4 (100.0%)	17 (94.4%)

Efficacy: Overall ORR 44.4%, DCR 94.4% (n=18)

In the 3mg/kg group, **2 CR**, **4 PR**, ORR **54.5%**, DCR **100%** (n=11)

Safety: Grade 3 and above **irAE 16.7%** (3/18)

Grade 3 and above **KN046-related TRAEs 16.7%** (3/18)

Relevant clinical progress: A phase Ⅱ clinical study (KN046-204) of ESCC is ongoing; data to be released in ESMO (Sep 2021)

2 Comparable trials

	KN046-IST-01	KEYNOTE 590	RATIONALE 205
Drug	KN046+ concurrent chemoradiation	Pembrolizumab + chemo VS chemo	Tislelizumab + chemo
Patients #	11	548	15
ORR	**54.5% (2 CR, 4 PR)**	45% VS 29.3%	46.7% (7 PR)

Notes: The KEYNOTE 590 trial contains data on esophageal squamous cell carcinoma and esophageal adenocarcinoma. The ORR is not reported separately, and is data for the entire population (n=749).

KN046-203 1L TNBC (2021 AACR)

1 Preliminary efficacy of KN046 plus nab-paclitaxel in 1L TNBC

Waterfall plot (ORR 40%, DCR 96%)



PFS (13.8 months in PD-L1 positive group)



OS (15 months OS rate 77.1%)



2 Comparable trials in 1L TNBC

	KN046-203	KEYNOTE-355	IMpassion130
Drug	KN046+chemo (nab-paclitaxel)	Keytruda+chemo VS chemo (nab-paclitaxel, paclitaxel, or oremcitabine plus carboplatin)	Tecentriq+chemo VS chemo (nab-paclitaxel)
Patients #	11 (PD-L1 positive)	425 VS 211 (PD-L1 positive)	185 VS 184 (PD-L1 positive)
mPFS	**13.8 months**	7.6 months VS 5.6 months	7.5 months VS 5.0 months
mDOR	**13.7 months**	not reached yet	8.5 months VS 5.5 months
mOS	not reached yet; 15 months OS rate **77.1%**	not reached yet	25.0 months VS 15.5 months; 15 months OS rate 67.0%

Note1: data cut-off date Mar 8, 2021; trial ongoing
Note 2: KN046-203 use patients in IC PD-L1≥1% subgroup，KEYNOTE-355 use patients in CPS≥1 subgroup, IMpassion130 use patients in TPS≥1% subgroup

KN026: HER2/HER2 BsAb

Mechanism of action



Highlights

- Dual blockade of parallel HER2-related signaling pathways
- Enhanced multiple HER2 receptor binding and internalization
- Fc-based BsAb with full effector functions

KN026, JSKN003, KN026+KN046 Combo Major Clinical Trials

Tumor Type	Trial	Combo/Mono	Expected timeline
HER2+BC	KN026-304	≥ 2L: KN026-based combination	BLA 2023H1 ★
	KN026-203, exploratory phase	≥ 2L: KN026 + KN046	Ongoing
	KN026-201 SANOFI	1L: KN026 + docetaxel	Ongoing
		≥ 2L: KN026 + pyrotinib/capecitabine	FPI 2021Q2
	KN026-205 Pfizer	≥ 2L: KN026 + palbociclib (+/- fulvestrant)	FPI 2021Q2
HER2+GC/GEJ	KN026-203, primary efficacy phase	≥ 2L: KN026 + KN046	BLA 2023H2 ★
	KN046-IST-02	1L: KN026 + KN046	Ongoing
		1L: KN026 + KN046 + reduced chemo	FPI 2021Q2
	KN026-202	≥ 2L: mono	Ongoing
HER2+ solid tumors	JSKN003-101	Late line: mono	BLA 2023H2 ★
	KN026-US-01	Late line: mono	Ongoing
	KN046-IST-02, exploratory phase	≥ 2L: KN026 + KN046	Ongoing
	KN026-203, exploratory phase	≥ 2L: KN026 + KN046	Ongoing
HER2-low solid tumors	JSKN003-101	Late line: mono	FPI 2022Q2

★ Pivotal Trial

Note: FPI – first patient in

KN026-CHN-001

KN026 is well tolerated and has demonstrated encouraging anti-tumor activity in HER2-positive breast cancer patients who have failed standard anti-HER2 therapies.

Waterfall plot



Progression-free survival (6.8 months at RP2Ds)



Overall survival (1-year OS rate at RP2Ds 90.3%)



- Median age: 54 (range: 31~69)
- Median prior lines of HER2 target therapies: 2 (range: 1~12)
- **mPFS 6.8 months at RP2Ds**
  - 5.5 months at 20 mg/kg Q2W
  - 7.4 months at 30 mg/kg Q3W
- **1-year OS rate at RP2Ds 90.3%**

Note: data cut-off 21-Dec-2020

A PK Model to Predict Efficacious Doses for KN026 (2020 AACR)

20 mg/kg Q2W and 30 mg/kg Q3W provide adequate steady state trough concentration for efficacy





☑ **Facilitate decision of effective dose and dose schedule, improve efficiency of R&D**

KN026 has shown favorable PK profile compared with ZW25



☑ **Favorable PK profile of KN026: 30 mg/kg Q3W**

KN046+KN026: KN046-IST-02 HER2 Positive Solid Tumors (2020 SITC)

- ✓ ORR **64.3%**, DCR **92.9%** (n=14)
- ✓ Responses were observed in 10 patients who failed previous HER2 and/or ICI treatment



	20 mg/kg Q2W + 3 mg/kg Q2W （N=13）	20 mg/kg Q2W + 5 mg/kg Q3W （N=1）	30 mg/kg Q3W + 5 mg/kg Q3W （N=0）	Total （N=14）
Best Overall Response				
Complete Response (CR)	0	0	0	0
Partial Response (PR)	8 (61.5%)	1 (100%)	0	9 (64.3%)
Stable Disease (SD)	4 (30.8%)	0	0	4 (28.6%)
Progressive Disease (PD)	1 (7.7%)	0	0	1 (7.1%)
Not Evaluable (NE)	0	0	0	0
Objective Response Rate (ORR)	8 (61.5%)	1 (100%)	NA	**9 (64.3%)**
95% CI	31.6%, 86.1%	2.5%, 100.0%	NA	35.1%, 87.2%
Disease Control Rate (DCR)	12 (92.3%)	1 (100.0%)	NA	**13 (92.9%)**
95% CI	64.0%, 99.8%	2.5%, 100.0%	NA	66.1%, 99.8%

Notes:

1. Prior T: previously treated by trastuzumab; Prior PD-1: previously treated by anti-PD-1 agent; Duo: duodenum; UNK: unknown origin

Potential Superior Efficacy: ≥ 2L Gastric Cancer Studies

Target best in class profile with near-term US and China registration studies



KN035: Potential First-global SubQ PD-L1 with BLA Submitted in China

Intravenous infusion vs. subcutaneous Injection



Intravenous Infusion

subcutaneous Injection

- BLA (MSI-H/dMMR advanced solid tumors) submitted in China in 2020Q4
- Priority review granted by NMPA
- BLA approval expected by the end of 2021

Advantages

- Easier administration
- More convenient for maintenance usage
- More efficient utilization of medical resources
- Preferred for patients with limited vein access and infusion related reactions
- Better safety profile

KN035: Clinical Development Summary – Collaboration with 3DMed

Study	Phase 1	Phase 1b	Phase 2	Pivotal Study (Phase 2/3)	BLA	Progress
CN006	Pan-cancer (>15 solid tumors) with MSI-H					BLA submitted in China
CN005	Monotherapy | Single-arm, ORR | 2L/3L		Biliary tract cancer			>95% recruitment
CN007	Combo with chemo | Open-labeled, randomized, two-arm parallel, OS | 1L		Gastric cancer			Completed
CN001	Combo with chemo | Single-arm, exploratory | 1L		Dose escalation/expansion			Completed
JP001	Monotherapy Safety and efficacy		Dose escalation/exploration			Completed
US001	Monotherapy Safety and efficacy		Dose escalation/exploration			Full enrolled
CN008		PD1 failure NSCLC (+chidamide)				IND
CN009			Randomized, 1st line NSCLC (Non-inferiority Ph3)			Pre registration meeting
CN010		-PD(L)1 failure NSCLC, RCC, HCC (+lenvatinib) -1st line RCC (+lenvatinib)				Pre-IND
CN011			Single arm, 2nd line MSS Endometrial Cancer (+lenvatinib			Pre registration meeting
CN012			Single arm, 2nd line TMB high tumors			Preliminary response rec'd
CN013			Randomized, 1st line maintenance, UC			Pre registration meeting

KN035: Clinical Development Summary – Collaboration with Tracon in UPS/MFS in US

Key Milestones



- ✓ US FDA Type B meeting on May 2021
- ✓ 10 patients enrolled as of Mar 2021

KN035 Efficacy Comparison: VS Pembrolizumab and Nivolumab in Advanced dMMR/MSI-H Solid Tumors

	Pembrolizumab			Nivolumab[3,4]	Envafolimab		
	KEYNOTE-164[1]		KEYNOTE-158[2]	CHECKMATE-142	KN035-CN-006		
Study population	CRC-cohort A (≥2 prior therapies CRC) • Local/central lab verified MSIH/dMMR;	CRC-cohort B (overall CRC) • Local/central lab verified MSIH/dMMR;	non-CRC (prior ≥ 1 line) • Local/central lab verified MSIH/dMMR	≥2 prior therapies CRC • Local/central lab verified MSIH/dMMR	≥2 prior therapies CRC • Central lab verified MSIH;	Overall CRC • Central lab verified MSIH;	Overall population (prior ≥ 1 line) • Site/central lab verified MSIH/dMMR;
Sample size	61	63	233	53	41	65	103
ORR, %; IRC	33% (27.9%*)	33% (32%*)	34.3%	28%	31.7%	43.1%	42.7%
mPFS, months	2.3	4.1	4.1	—	4.9	7.2	11.1
6-m PFS rate	— (43%*)	— (49%*)	—	—	48.8%	53.8%	57.7%
mOS (months)	31.4	not reached	23.5	—	not reached	not reached	not reached
6-m OS rate	— (87%*)	— (84%*)	—	—	80.5%	84.5%	82.4%
12-m OS rate	72%	76%	60.7%	73%	64.7%	72.9%	74.6%

*: KEYNOTE164 early published data [5,6]
3 drugs failed: failed with Fluorouracil, Oxaliplatin, Irinotecan
2 drugs failed: failed with Fluorouracil combined with oxaliplatin/irinotecan

1. J Clin Oncol. 2020 Jan 1;38(1):11-19.
2. J Clin Oncol. 2020; 38 (1): 1-10.
3. Overman MJ, et al. Lancet Oncol. 2017; 18(9): 1182-1191.
4. Opdivo (nivolumab). Highlights of Prescribing Information. Reference ID: 4427750ite
5. Annals of Oncology. 2017; 28(S5): 128-129.
6. ASCO 2018 Annual Meeting, 3514.

KN035: Superior Safety Profile and Dosing Schedule

1 irAE Comparison of KN035 and similar products

All levels of incidence (%)	PD-1 inhibitor					PD-L1 inhibitor			
	Nivolumab[1] (n=1994)	Pembrolizumab[2] (n=2799)	Sintilimab[3] (n=540)	Toripalimab[4] (n=598)	Camrelizumab[5] (n=986)	Avelumab[6] (n=1629)	Durvalumab[7] (n=1889)	Atezolizumab[8] (n=2616*)	KN035 (n=390)
Immune-related pneumonia	3.1%	3.4%	6.9%	1.8%	2.7%	1.2%	5%	2.5%	0.5%
Immune-related colitis	2.9%	1.7%	0%	0%	0.2%	1.5%	-	1.0%[9*]	0%
Infusion reaction	6.4%	3.0%[10*]	-	-	-	25%	2.2%	1.3%	NA[#]
Immune-related endocrine diseases									
Hypothyroidism	9%	8.5%	8.5%	12.9%	20.5%	5%	11%	4.6%	11.8%
Hyperthyroidism	2.7%	3.4%	4.3%	4.8%	6.7%	0.4%	7%	1.6%	7.2%
Immune related myocarditis	< 1%	< 1%	0.6%	-	0.3%	< 1%	< 1%	< 1%	0.3%
Immune related hepatitis	1.8%	0.7%	3.5%	3.5%	9.1%	0.9%	12%	9%	2.8%

2 PK simulation support future change from QW to Q3W



*: Atezolizumab's immune-related colitis (1.0%; n+729); pembrolizumab's infusion reaction (3.0%; n=495)
-: Not reported
#: KN035 has no infusion reaction due to subcutaneous injection, and the incidence of injection site reaction is 5.1% (all Grade 1-2)

1. OPDIVO (nivolumab). HIGHLIGHTS OF PRESCRIBING INFORMATION. Reference ID: 4400635
2. KEYTRUDA (pembrolizumab). HIGHLIGHTS OF PRESCRIBING INFORMATION. Reference ID: 4492828
3. March 2019, Sintilimab (CXSS1800008) BLA technical review report by NMPA CDE
4. March 2019, Toripalimab(CXSS1800006) BLA technical review report by NMPA CDE
5. July 2019, Camrelizumab (CXSS1800009) BLA technical review report by NMPA CDE
6. BAVENCIO (avlumab). HIGHLIGHTS OF PRESCRIBING INFORMATION. Reference ID: 4433254
7. IMFINZI (durvalumab). HIGHLIGHTS OF PRESCRIBING INFORMATION. Reference ID: 4465139
8. TECENTRIQ (atezolizumab). HIGHLIGHTS OF PRESCRIBING INFORMATION. Reference ID: 4527935
9. Wang DY, et al. Onco 2017; 6: e1344805 10. Garon E B, et al. N Engl J Med, 2015, 372(21)

KN019: CTLA-4 Fusion Protein - Immunosuppressant Drug

Mechanism of action



Clinical development progress

- China phase II RA study :

  Completed patients enrollment (N~140)

- Expected data readout in 2021Q3

- Plan to initiate a bioavailability study to switch from IV formulation to subQ in 2021

- Plan to initiate phase III for RA in 2022H2

康宁杰瑞
ALPHAMAB ONCOLOGY



04

Operation Progress

Expansion of Management Team

Chief Financial Officer
Weihao Xu

- +15 years experiences in global capital market, equity investment and financial management
- Served as Chief Financial Officer for CASI Pharmaceuticals and 111 Inc.. In the area of investment, he served as a Portfolio Manager and analyst in Matthews International and several other international funds
- Master of Philosophy degree in Finance and Accounting from Columbia Business School and also completed High Impact Cancer Research, a postgraduate program at Harvard Medical School

Chief Medical Officer
Dr. Johannes Nippgen

- 25+ years of pharmaceutical industry and clinical oncology experience
- Served as senior and consultant oncologist in German Dresden University and in R&D leadership positions in various international biopharma and biotech companies, most recently as Head of R&D in China for Merck
- Doctoral degree in Medicine from Wurzburg- and Clinical Medicine degree from Mainz- University (Germany), German and European board certifications in Urology/GU-oncology

Business Development: Comprehensive Combo Strategy

..to unlock KN046's full potential

Target	Combo Drug	Partner
VEGFR-1, VEGFR-2, VEGFR-3	Inlyta ® (axitinib)	Pfizer
VEGFR-1, -2, -3; c-CRAF, BRAF, mBRAF; FLT3; KIT; PDGFRβ; RET, RET/PTC	Donafenib Tosylate	**Zelgen** 泽璟制药
MET; VEGFR-2; AXL; MER; FLT-3	Ningetinib Toluenesulfonate CT053	**Sunshine Lake** 广东东阳光
ALK-1 (Activin Receptor-Like Kinase-1)	GT90001	**Kintor Pharmaceutical** 开拓药业
Wnt pathway Porcupine protein	XNW7201	**Sinovent** 信诺维
Focal adhesion kinase inhibitor	IN10018	**InxMed/Cornell University** 应世生物/康奈尔大学

Business Development: Strong MNC Interest in KN026

HER2-positive, HER2-int/low and HER2-mutation, KN026-based combination

Target	Combo Drug	Partner
CDK4/6	Ibrance® (palbociclib)	Pfizer
Microtubule inhibitor	Taxotere®[3] (Docetaxel)	SANOFI

Notes:

1. Herceptin's label only covers Her-2 High, about 25% of breast cancer patients. While total Her-2 High, Midium and Low is about 80% of patients
2. Herceptin's label only covers Her-2 High, about 10-18% of gastric cancer patients. While total Her-2 High, Midium and Low is about 40% of patients
3. Sanofi has an exclusive option agreement for the strategic collaboration to advance clinical studies investigating KN026

Strong Manufacturing Capabilities

- ✓ The Phase I (2x2,000L) production lines of our new manufacturing facilities has obtained **Drug Production License** by Jiangsu Provincial Drug Administration in June, 2020
- ✓ Jiangsu Alphamab passed on-site inspection of **EU Qualified Person** in February, 2020
- ✓ Current capacity: **6,000L** (2x2,000L, 2x1,000L)
- ✓ Extra **6,000L** to be retrofit to current facility in 2022
- ✓ Construction of additional **30,000L** manufacturing to be initiated in 2022

康宁杰瑞
ALPHAMAB ONCOLOGY



05

2021 Catalyst

Key Upcoming Milestones and Catalyst in 2021

Pivotal Trials

- ✓ To complete enrollment and generate interim readout for ENREACH-LUNG-01: KN046+chemo, **1L sq-NSCLC**
- ✓ To complete enrollment for ENREACH-THYMIC: KN046 **≥ 2L thymic carcinoma**
- ✓ To initiate pivotal trial: KN046+lenvatinib, **PD-(L)1 refractory NSCLC**
- ✓ To initiate pivotal trial: KN046+chemo, **1L pancreatic cancer**

Key Data Release

- ✓ AACR (Apr, 2021, presentation accepted): KN046-203 TNBC
- ✓ ASCO (Jun, 2021, abstract accepted):
  1) KN026-202 GC
  2) KN046-204 1L ESCC
  3) KN046-202 1L NSCLC
  4) KN046-IST-04 1L pancreatic cancer
- ✓ ESMO (Sep, 2021, planning-stage):
  1) KN046-202 driver mutation positive NSCLC
  2) KN046-IST-02 KN046+KN026 HER2-positive solid tumors
  3) KN046-IST-05 1L HCC
- ✓ SITC (Dec, 2021, planning-stage):
  1) KN026-203 KN046+KN026 ≥2L HER2+ BC
  2) KN046-302 trail design for KN046+Ningetinib in PD-(L)1 refractory NSCLC
- ✓ SABC (Dec, 2021, planning-stage): KN026-201 1L BC

Key Upcoming Milestones and Catalyst in 2021

IND

- ✓ 2-3 IND applications for new drug candidates: **Her-2 ADC**, **KN052** and **COVID-19 antibody**
- ✓ **KN019** to be converted to subcutaneous injection form for cancer/non-cancer indications

Business Development

- ✓ Co-development/out-license deal for **KN035** and **KN026**

Commercialization

- ✓ KN035 (Envafolimab) **BLA approval**
- ✓ Building **a core commercial team**

Manufacturing and Quality

- ✓ Pilot plant with advanced process technology
- ✓ **Extra 6,000L** to be retrofit to current facility

Other

- ✓ State-of-art 12,000 m^2 **research lab** to enable protein design, engineering, process development, cell therapy and gene therapy

康宁杰瑞
ALPHAMAB ONCOLOGY

06

Financial Highlight

Increased R&D Expense Due to Expansion and Advancement of Clinical Trials

For the year ended December 31, 2019

RMB ('000) (audited)



For the year ended December 31, 2020

RMB ('000) (audited)



Consolidated Statement of Comprehensive Income

(RMB'000)	For the year ended December 31	
	2019 (audited)	**2020 (audited)**
Other income	34,429	111,136
Other losses	(321)	(117,627)
Fair value change of convertible redeemable preferred shares	(542,291)	-
Research and development expenses	(166,654)	(331,241)
Administrative expenses	(117,736)	(78,208)
Finance costs	(3,606)	(11,826)
Listing expenses	(36,561)	-
Loss before taxation	(832,740)	(427,766)
Income taxation	-	-
Loss for the year	**(832,740)**	**(427,766)**

Balance Sheet

(RMB'000)	As of 31 December 2019 (audited)	As of 31 December 2020 (audited)
Non-current assets		
Property, plant and equipment	331,951	361,030
Right-of-use assets	42,353	31,991
Deposits paid for acquisition of property, plant and equipment	4,321	12,797
Other receivables and deposits	31,490	34,476
	410,115	**440,294**
Current assets		
Inventories	25,918	44,321
Other receivables, deposits and prepayments	36,115	84,795
Financial assets at fair value through profit or loss ("FVTPL")	11,680	43,530
Derivative financial instruments	-	5,863
Time deposits with original maturity over three months	502,889	1,835,398
Cash and cash equivalents	1,867,866	185,321
	2,444,468	**2,199,228**
Current liabilities		
Trade and other payables	145,962	121,939
Amount due to a related company	787	3,765
Lease liabilities - current portion	13,081	10,146
Bank borrowings - current portion	28,750	188,000
Contract liabilities - current portion	-	469
Deferred income	11,950	5,216
	200,530	**329,535**
Net current assets	**2,243,938**	**1,869,693**
Total assets less current liabilities	**2,654,053**	**2,309,987**
Non-current liabilities		
Lease liabilities - non-current portion	10,095	3,309
Contract liabilities - non-current portion	11,733	12,244
Bank borrowings - non-current portion	201,250	21,350
Deferred income - non-current portion	5,050	-
	228,128	**36,903**
Net assets	**2,425,925**	**2,273,084**
Capital and reserves		
Share capital	12	13
Reserves	2,425,913	2,273,071
Total equity (equity deficiency)	**2,425,925**	**2,273,084**

康宁杰瑞
ALPHAMAB ONCOLOGY



07

Q&A